Seer Bets on AI-Driven Deep Proteomics as Revenue Stumbles
Despite declining top-line, Seer doubles down on population-scale studies, mass spec, and IP defense to unlock biomarker discovery at scale.
SEER · Earnings Call · 2026-08-11
A Defensive Pivot into Data-Driven Proteomics
Seer's second-quarter results show a company deliberately trading near-term revenue for long-term strategic positioning. Revenue of $3.1 million was down 34% year-over-year, but management was quick to frame the numbers as a byproduct of an "academic funding environment" rather than a failure of execution. CEO Omid Farokhzad was blunt: “Revenue at this stage does not reflect the value of what we're building.” — Omid Farokhzad, CEO · 2026-08-11 The company instead pointed to a series of validation milestones—95 publications, a Nature Genetics study, and the first 10,000-sample completion of the PRECISE-SG-100K cohort—as evidence that the AI models and plasma proteomic workflows they enable are gaining scientific traction.The AI & Population-Scale Bet
The most compelling element of the call was the convergence of deep unbiased proteomics with mass spectrometry and AI. At ASMS, Seer and Korea University presented preliminary data on AI-driven multi-cancer screening generated from thousands of samples on the Proteograph platform. Omid explained why this matters: “the future of proteome in an unbiased way is actually uniquely positioned well to fit the needs of the AI models ... the universe of the proteome is very large. And what we have identified to date is just a tip of the needle.” — Omid Farokhzad, CEO · 2026-08-11 The company is positioning its population scale studies—like PRECISE—as the flywheel that will unlock biobank commitments and eventually drive AI model training. CFO David Horn reaffirmed guidance of $16–18 million for the year, citing increasing customer conversations globally supported by the ASMS data and the upcoming HUPO presentation: “We are reaffirming guidance again because we do feel confidence in terms of what we're seeing in terms of the positive customer conversations.” — David Horn, CFO · 2026-08-11Defending the Moat
Seer is also aggressively defending its intellectual property. The PTAB upheld key patent claims against Bruker, the EPO upheld equivalent European claims, and an ITC investigation was opened against Nanomics. This is a strategic move to protect the nanoparticle enrichment core, especially as imitators emerge. In a prior call, Omid had framed the litigation as protecting customers: “we filed the lawsuit, Kyle, because we want to make sure that our customers are served appropriately.” — Omid Farokhzad, CEO · 2026-05-13 That theme persists. The company's imitators are a recurring threat, and the IP defense is now a more visible part of the narrative.Financial Reality Check
Despite the narrative, the fundamentals remain challenging. Total Revenue for the quarter was $3M, and gross margin compressed to 35.2%, though management noted sequential improvement to 49% on a reported basis. The balance sheet remains strong with $209.5M cash, enabling buybacks that have reduced net share count by 15%. The stock, down 97% from its January 2021 peak, has rallied 20% over the last 90 days, suggesting investors are beginning to price in the long-term optionality. The prior call had pointed to the 9–12 month lag in pull-through: “it takes about 9 to 12 months before we see customers reorder given that they generally take a nice stocking order with their instrument purchase or with the loaner.” — David Horn, CFO · 2026-05-13 That expectation is now a key driver for the second-half ramp.What Changes?
What's genuinely new is the elevation of AI as a core part of Seer's value proposition, and the tangible progress on PRECISE. The company is betting that biomarker discovery at scale will eventually translate into revenue, but the timeline remains uncertain. The prior call had set the expectation for a 100,000-sample mass spec study by 2026:That prediction now seems dependent on closing large biobank deals, which are inherently lumpy. The reaffirmed guidance suggests confidence, but the yoy decline in Q2 shows the pressure is real. In the end, Seer is offering a story of scientific inflection over commercial one. The install base and pull-through are expected to drive second-half performance, but the immediate numbers remain weak. Investors holding the stock are effectively buying an option on mass-spectrometry scale and AI-driven discovery.my prediction, by the way, is that, the first study of 100,000 sample using mass spec is right around the corner, probably in 2026.